HUMAN NEUREGULIN-1 RECOMBINANT (177-237)

Summary

Human Neuregulin-1 Recombinant (177-237) (CHEMBL4594600) is a phase-3 clinical-stage unknown; indicated across 2 conditions including heart failure and systolic heart failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594600
Name	HUMAN NEUREGULIN-1 RECOMBINANT (177-237)
Type	Unknown
Max phase	3

Also known as: Neucardin, Rhnrg-1

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
heart failure	3	MONDO:0005252	EFO:0003144
systolic heart failure	3	MONDO:0006993	EFO:1001207

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	7

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01131637	PHASE3	TERMINATED	Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
NCT01214096	PHASE3	TERMINATED	Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
NCT01439789	PHASE3	TERMINATED	Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
NCT01439893	PHASE3	TERMINATED	Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients
NCT01541202	PHASE3	TERMINATED	Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
NCT03388593	PHASE3	UNKNOWN	Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
NCT05949801	PHASE3	COMPLETED	Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).